| Product Code: ETC8540719 | Publication Date: Sep 2024 | Updated Date: Nov 2025 | Product Type: Market Research Report | |
| Publisher: 6Wresearch | Author: Vasudha | No. of Pages: 75 | No. of Figures: 35 | No. of Tables: 20 |
The Netherlands continues to be a key importer of insulin biosimilars, with Belgium, Hungary, USA, Japan, and Sweden emerging as top exporting countries in 2024. Despite a high concentration with a high Herfindahl-Hirschman Index (HHI) in 2024, indicating market dominance by a few key players, the compound annual growth rate (CAGR) from 2020 to 2024 stands at a steady 3.85%. However, there was a notable decline in growth rate from 2023 to 2024, dropping by -42.93%, suggesting potential shifts or challenges in the market landscape.

1 Executive Summary |
2 Introduction |
2.1 Key Highlights of the Report |
2.2 Report Description |
2.3 Market Scope & Segmentation |
2.4 Research Methodology |
2.5 Assumptions |
3 Netherlands Insulin Biosimilars Market Overview |
3.1 Netherlands Country Macro Economic Indicators |
3.2 Netherlands Insulin Biosimilars Market Revenues & Volume, 2021 & 2031F |
3.3 Netherlands Insulin Biosimilars Market - Industry Life Cycle |
3.4 Netherlands Insulin Biosimilars Market - Porter's Five Forces |
3.5 Netherlands Insulin Biosimilars Market Revenues & Volume Share, By Product Type, 2021 & 2031F |
3.6 Netherlands Insulin Biosimilars Market Revenues & Volume Share, By Indicative, 2021 & 2031F |
3.7 Netherlands Insulin Biosimilars Market Revenues & Volume Share, By End User, 2021 & 2031F |
4 Netherlands Insulin Biosimilars Market Dynamics |
4.1 Impact Analysis |
4.2 Market Drivers |
4.2.1 Increasing prevalence of diabetes in the Netherlands |
4.2.2 Growing demand for cost-effective insulin therapies |
4.2.3 Favorable government initiatives promoting the use of biosimilars |
4.3 Market Restraints |
4.3.1 Stringent regulatory requirements for biosimilars approval |
4.3.2 Limited awareness and acceptance of biosimilars among healthcare professionals and patients |
5 Netherlands Insulin Biosimilars Market Trends |
6 Netherlands Insulin Biosimilars Market, By Types |
6.1 Netherlands Insulin Biosimilars Market, By Product Type |
6.1.1 Overview and Analysis |
6.1.2 Netherlands Insulin Biosimilars Market Revenues & Volume, By Product Type, 2021- 2031F |
6.1.3 Netherlands Insulin Biosimilars Market Revenues & Volume, By Rapid-acting biosimilar, 2021- 2031F |
6.1.4 Netherlands Insulin Biosimilars Market Revenues & Volume, By Long-acting biosimilar, 2021- 2031F |
6.1.5 Netherlands Insulin Biosimilars Market Revenues & Volume, By Premixed biosimilar, 2021- 2031F |
6.2 Netherlands Insulin Biosimilars Market, By Indicative |
6.2.1 Overview and Analysis |
6.2.2 Netherlands Insulin Biosimilars Market Revenues & Volume, By Type I Diabetes, 2021- 2031F |
6.2.3 Netherlands Insulin Biosimilars Market Revenues & Volume, By Type II Diabetes, 2021- 2031F |
6.3 Netherlands Insulin Biosimilars Market, By End User |
6.3.1 Overview and Analysis |
6.3.2 Netherlands Insulin Biosimilars Market Revenues & Volume, By Hospitals, 2021- 2031F |
6.3.3 Netherlands Insulin Biosimilars Market Revenues & Volume, By Ambulatory Surgical Centers, 2021- 2031F |
6.3.4 Netherlands Insulin Biosimilars Market Revenues & Volume, By Others, 2021- 2031F |
7 Netherlands Insulin Biosimilars Market Import-Export Trade Statistics |
7.1 Netherlands Insulin Biosimilars Market Export to Major Countries |
7.2 Netherlands Insulin Biosimilars Market Imports from Major Countries |
8 Netherlands Insulin Biosimilars Market Key Performance Indicators |
8.1 Adoption rate of insulin biosimilars in healthcare facilities |
8.2 Number of clinical trials and research studies on insulin biosimilars in the Netherlands |
8.3 Average cost savings achieved through the use of insulin biosimilars compared to originator products |
9 Netherlands Insulin Biosimilars Market - Opportunity Assessment |
9.1 Netherlands Insulin Biosimilars Market Opportunity Assessment, By Product Type, 2021 & 2031F |
9.2 Netherlands Insulin Biosimilars Market Opportunity Assessment, By Indicative, 2021 & 2031F |
9.3 Netherlands Insulin Biosimilars Market Opportunity Assessment, By End User, 2021 & 2031F |
10 Netherlands Insulin Biosimilars Market - Competitive Landscape |
10.1 Netherlands Insulin Biosimilars Market Revenue Share, By Companies, 2024 |
10.2 Netherlands Insulin Biosimilars Market Competitive Benchmarking, By Operating and Technical Parameters |
11 Company Profiles |
12 Recommendations |
13 Disclaimer |
Export potential enables firms to identify high-growth global markets with greater confidence by combining advanced trade intelligence with a structured quantitative methodology. The framework analyzes emerging demand trends and country-level import patterns while integrating macroeconomic and trade datasets such as GDP and population forecasts, bilateral import–export flows, tariff structures, elasticity differentials between developed and developing economies, geographic distance, and import demand projections. Using weighted trade values from 2020–2024 as the base period to project country-to-country export potential for 2030, these inputs are operationalized through calculated drivers such as gravity model parameters, tariff impact factors, and projected GDP per-capita growth. Through an analysis of hidden potentials, demand hotspots, and market conditions that are most favorable to success, this method enables firms to focus on target countries, maximize returns, and global expansion with data, backed by accuracy.
By factoring in the projected importer demand gap that is currently unmet and could be potential opportunity, it identifies the potential for the Exporter (Country) among 190 countries, against the general trade analysis, which identifies the biggest importer or exporter.
To discover high-growth global markets and optimize your business strategy:
Click Here